In late February, the stock re-entered penny stock territory in the wake of a failed late-stage trial for its respiratory syncytial vaccine candidate ResVax. The company subsequently enacted a 1 …
More Novavax Takes Accelerated Approval Pathway For Flu Vaccine Development Videos